Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy

Journal:

Kidney International

Published:

2025-06-27

DOI:

10.1016/j.kint.2025.05.028

Affiliations:

6

Authors:

13

Go to article

Institutions	Authors	Share
HI-Bio, United States of America (USA)	5.000000	0.38
MorphoSys, Germany	4.000000	0.31
University of Leicester, United Kingdom (UK)	1.000000	0.08
Stanford Medicine, United States of America (USA)	1.000000	0.08
The University of British Columbia (UBC), Canada	1.000000	0.08
University Hospital Aachen (UKA), RWTH Aachen, Germany	1.000000	0.08

Interested in Oncology and Carcinogenesis?